BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinib
Open Access
- 1 January 2018
- journal article
- letter
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 103 (1), e10-e12
- https://doi.org/10.3324/haematol.2017.176347
Abstract
The third-generation tyrosine kinase inhibitor (TKI) ponatinib exerts a strong anti-neoplastic effect in all stages of chronic myeloid leukemia (CML) as well as in Philadelphia(Ph)-positive acute lymphoblastic leukemia (ALL). It is capable of suppressing the kinase activity of BCR-ABL1 carrying anyKeywords
This publication has 16 references indexed in Scilit:
- Analysis of the Sub-Clonal Origins of Compound Mutations in Patients with Refractory Ph+ Malignancies Treated with PonatinibBlood, 2016
- Transposon-mediated generation of BCR-ABL1-expressing transgenic cell lines for unbiased sensitivity testing of tyrosine kinase inhibitorsOncotarget, 2016
- Long-Term Side Effects of Tyrosine Kinase Inhibitors in Chronic Myeloid LeukemiaCurrent Hematologic Malignancy Reports, 2016
- Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patientsBlood, 2016
- Long-Term Follow-up of Ponatinib Efficacy and Safety in the Phase 2 PACE TrialBlood, 2014
- BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive LeukemiaCancer Cell, 2014
- Comprehensive Analysis Of The In Vitro Potency Of Ponatinib, and All Other Approved BCR-ABL Tyrosine Kinase Inhibitors (TKIs), Against a Panel Of Single and Compound BCR-ABL MutantsBlood, 2013
- Ponatinib in Refractory Philadelphia Chromosome-Positive LeukemiasThe New England Journal of Medicine, 2012
- AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based ResistanceCancer Cell, 2009
- Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potencyJCI Insight, 2007